News und Analysen
![As COVID-19 Pushes Hospital Patients to Post-Acute Care Settings, Supply and Resource Needs Grow, Per Premier Inc. Survey](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
As COVID-19 Pushes Hospital Patients to Post-Acute Care Settings, Supply and Resource Needs Grow, Per Premier Inc. Survey
Senior nursing and assisted living facilities have limited personal protective equipment (PPE) to care for a greater volume of patients, according to a Premier Inc. survey – indicating a second
![QIAGEN Announces Preliminary Q1 2020 Results](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
QIAGEN Announces Preliminary Q1 2020 Results
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary sales and adjusted earnings per share results for the first quarter of 2020.
Net sales rose approximately 9% at
![QIAGEN gibt vorläufige Ergebnisse des ersten Quartals 2020 bekannt](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
QIAGEN gibt vorläufige Ergebnisse des ersten Quartals 2020 bekannt
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gibt die vorläufigen Umsatzergebnisse und den vorläufigen bereinigten Gewinn je Aktie für das erste Quartal 2020 bekannt.
Der bereinigte
![ICON Signs New Service Agreement With Pfizer](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
ICON Signs New Service Agreement With Pfizer
ICON plc, (NASDAQ: ICLR) a leading global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced
![Novocure Provides Business Update Related to COVID-19](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Novocure Provides Business Update Related to COVID-19
Novocure (NASDAQ: NVCR) today provided an update on its response to the global COVID-19 pandemic and an initial evaluation of the impact the pandemic may have on Novocure’s general business
![Premier Inc. Pursues Crucial Strategies to Get Supplies, Enable Care Delivery During COVID-19](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Premier Inc. Pursues Crucial Strategies to Get Supplies, Enable Care Delivery During COVID-19
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, is coordinating across the industry to help solve the supply chain challenges presented by COVID-19. Success will rely on
![Premier Inc. Survey: As COVID-19 Spreads to New Hotspots, Hospitals Should Prepare for up to a 17X Surge in Supply Demand](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Premier Inc. Survey: As COVID-19 Spreads to New Hotspots, Hospitals Should Prepare for up to a 17X Surge in Supply Demand
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released survey results quantifying the surge capacity needed for personal protective equipment (PPE) and other supplies
![Premier Inc. Data Shows Drugs Essential to Providing Care for COVID-19 Patients Quickly Slipping into Shortage](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Premier Inc. Data Shows Drugs Essential to Providing Care for COVID-19 Patients Quickly Slipping into Shortage
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released data finding that 15 drugs essential to providing care for COVID-19 patients are currently in or very near
![QIAGEN Receives U.S. FDA EUA for QIAstat-Dx test kit, First and Only Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
QIAGEN Receives U.S. FDA EUA for QIAstat-Dx test kit, First and Only Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its newly developed
![QIAGEN erhält als erste und bisher einzige syndromische Testoption Notfallzulassung der FDA für QIAstat-Dx-Testpanel zum Nachweis des Coronavirus SARS-CoV-2](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
QIAGEN erhält als erste und bisher einzige syndromische Testoption Notfallzulassung der FDA für QIAstat-Dx-Testpanel zum Nachweis des Coronavirus SARS-CoV-2
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass es von der US-amerikanischen Arzneimittelzulassungsbehörde FDA eine Notfallzulassung (Emergency Use Authorization) für
![Update on 92nd Vifor Pharma Ltd. Annual General Meeting](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Update on 92nd Vifor Pharma Ltd. Annual General Meeting
Regulatory News:
Vifor Pharma confirmed that it will hold its Annual General Meeting (AGM) on 14 May, 2020, as planned. In view of the current situation and based on Art. 6a of Ordinance 2
![Update zur 92. Generalversammlung der Vifor Pharma AG](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Update zur 92. Generalversammlung der Vifor Pharma AG
Regulatory News:
Vifor Pharma hat bestätigt, dass die Generalversammlung des Unternehmens wie geplant am 14. Mai 2020 abgehalten wird. Aufgrund der aktuellen Situation und im Einklang mit Art. 6a
![LivaNova to Host Conference Call for First Quarter 2020 Results](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
LivaNova to Host Conference Call for First Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2020 results on Wednesday, April 29, 2020 at 1 p.m
![Charles River Laboratories and Deciphex Form a Partnership to Enhance Drug Discovery & Development With Digital Pathology](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Charles River Laboratories and Deciphex Form a Partnership to Enhance Drug Discovery & Development With Digital Pathology
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a partnership with Deciphex, a leader in preclinical digital pathology software-as-a-service.
![Gemeinsamer Bundesausschuss beschließt Aufnahme von TTFields in die Richtlinie Methoden Vertragsärztlicher Versorgung (MVV-RL)](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Gemeinsamer Bundesausschuss beschließt Aufnahme von TTFields in die Richtlinie Methoden Vertragsärztlicher Versorgung (MVV-RL)
Novocure (NASDAQ: NVCR) gab heute bekannt, dass der Gemeinsame Bundesausschuss (G-BA) die Ergänzung der MVV-RL um die Methode Tumortherapiefelder (TTFields) beschlossen hat. Optune ist somit für
![LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at American College of Cardiology and World Congress of Cardiology Virtual Meeting](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at American College of Cardiology and World Congress of Cardiology Virtual Meeting
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced two abstracts focused on implantable neuromodulation technology for patients with heart
![Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced it has entered
![QIAGEN ernennt Thierry Bernard zum Chief Executive Officer](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
QIAGEN ernennt Thierry Bernard zum Chief Executive Officer
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Ernennung von Thierry Bernard zum Chief Executive Officer bekannt gegeben.
Zusätzlich hat eine gemeinsame Sitzung des
![QIAGEN Names Thierry Bernard as Chief Executive Officer](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
QIAGEN Names Thierry Bernard as Chief Executive Officer
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Thierry Bernard has been named Chief Executive Officer.
Additionally, a Joint Meeting of the Supervisory Board and the
![QIAGEN Releases QIAstat-Dx Test Kit to the U.S. as First Syndromic Test for Detection of SARS-CoV-2 Coronavirus Under New FDA Policy](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
QIAGEN Releases QIAstat-Dx Test Kit to the U.S. as First Syndromic Test for Detection of SARS-CoV-2 Coronavirus Under New FDA Policy
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has begun shipments to the United States of its new QIAstat-Dx Respiratory SARS-CoV-2 Panel test to aid in diagnosing
![QIAGEN bietet ersten syndromischen QIAstat-Dx-Test zum Nachweis des Coronavirus SARS-CoV-2 in den USA unter neuen FDA Richtlinien an](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
QIAGEN bietet ersten syndromischen QIAstat-Dx-Test zum Nachweis des Coronavirus SARS-CoV-2 in den USA unter neuen FDA Richtlinien an
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute erste Lieferungen des neu entwickelten QIAstat-Dx-SARS-CoV-2-Atemwegspanel zur Diagnose von Patienten mit COVID-19-Infektion in die USA
![German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany
Novocure (NASDAQ: NVCR) today announced that the German Federal Joint Committee, or G-BA, has updated its directive for Contracted Medical Care to include Tumor Treating Fields, establishing
![Novocure Announces Optune Lua™ as the Brand Name for the NovoTTF-100L™ System](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Novocure Announces Optune Lua™ as the Brand Name for the NovoTTF-100L™ System
Novocure (NASDAQ: NVCR) announced today that Optune Lua is the brand name for the NovoTTF-100L System in malignant pleural mesothelioma (MPM). The U.S. Food and Drug Administration (FDA) previously
![QIAGEN führt in Europa QIAstat-Dx-Testkit zur Erkennung des neuartigen Coronavirus SARS-CoV-2 nach erfolgter CE-Kennzeichnung ein](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
QIAGEN führt in Europa QIAstat-Dx-Testkit zur Erkennung des neuartigen Coronavirus SARS-CoV-2 nach erfolgter CE-Kennzeichnung ein
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass das neu entwickeltes QIAstat-Dx-SARS-CoV-2-Atemwegs-Panel die CE-Kennzeichnung für den Verkauf als In-vitro-Diagnosetest